ImmuneOnco Biopharmaceuticals (Shanghai) Applies for Phase III Clinical Trial Approval of IMM0306 for Follicular Lymphoma in China(Note: There is no indication of grant/funding or involvement of multiple organizations in the provided announcement; the news is about a regulatory application for a Phase III clinical trial.)
I'm PortAI, I can summarize articles.
ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has submitted a Phase III clinical trial application for its investigational therapy, IMM0306, targeting follicular lymphoma, to the NMPA in China. IMM0306 is a bispecific molecule aimed at enhancing the immune response against malignant B cells. The company holds global rights to the drug but warns that successful development or commercialization is not guaranteed. No external funding was mentioned in the announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments